Akademik Veri Yönetim Sistemi
Turk Hijyen ve Deneysel Biyoloji Dergisi, cilt.74, sa.2, ss.175-184, 2017 (Scopus)
Lung carcinoma is the most common cause of cancer-related death in men among other cancer types in last years. The most recent and significant step in the treatment of the disease is the determination of the human genome structure and understanding of tumor biology. Pharmacogenomics examines tumordependent gene mutations to determine in which patient the drug will be more effective. Personalized treatments that are specified directly to disease by using pharmacogenomics methods are applied to cure patients with minimum side effects. Also, determining sensitivity of drug against tumor by examining gene mutations in patients plays a crucial role in selection and outcome of treatment. Patient-specific pharmacogenetic applications in lung carcinoma treatment and their effects on prognostic of disease were reviewed in this study.